NasdaqGS:ARQTBiotechs
Does Suvretta’s Trim and ZORYVE’s Pediatric Progress Change The Bull Case For Arcutis (ARQT)?
In the past quarter, New York City-based Suvretta Capital Management reduced its Arcutis Biotherapeutics stake by nearly 1.1 million shares, trimming the position by about US$35.78 million while still keeping it as the fund’s largest reported holding.
At the same time, Arcutis reported strong uptake of its flagship dermatology drug ZORYVE and secured FDA acceptance of a supplemental pediatric filing, underlining how institutional repositioning is intersecting with key commercial and...